The catalepsy treatment market size has grown strongly in recent years. It will grow from $87.07 billion in 2024 to $92.7 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to economic factors, awareness and education, healthcare infrastructure development, drug approvals and regulatory landscape, advancements in medical research.
The catalepsy treatment market size is expected to see strong growth in the next few years. It will grow to $123.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to investment and funding, global health trends, patient advocacy and awareness programs, healthcare policy changes, innovations in drug development. Major trends in the forecast period include collaborative research initiatives, neurostimulation therapies, regulatory landscape changes, patient advocacy and awareness, digital health integration.
The catalepsy treatment market is anticipated to experience growth due to the increasing prevalence of chronic diseases. Chronic conditions, characterized by lasting three months or longer and often progressing over time, impact a significant portion of the global population, particularly the elderly. Catalepsy, associated with toxic or infectious diseases linked to chronic illnesses, is on the rise, necessitating effective treatment. As of September 2022, the World Health Organization reported that approximately 41 million people, accounting for 74% of global deaths, succumb to chronic noncommunicable diseases (NCD) annually. Notably, 77% of NCD deaths occur in low- and middle-income countries. This escalation in chronic diseases is a driving force behind the growth of the catalepsy treatment market.
The increasing prevalence of neurological disorders is poised to contribute to the expansion of the catalepsy treatment market. Neurological disorders, encompassing various medical conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves, necessitate effective catalepsy treatment to manage symptoms, slow disease progression, enhance quality of life, and prevent or manage complications. According to The European Academy of Neurology, neurological disorders impact 1 in 3 individuals at some point in their lives, emphasizing the significant and widespread nature of these conditions. This growing prevalence of neurological disorders acts as a key driver for the catalepsy treatment market.
Product innovation is a significant trend gaining traction in the catalepsy treatment market. Leading companies in this field are concentrating on developing innovative solutions to enhance their market position. For example, in March 2024, Luigi Pavia, an Italy-based ecosystem engagement company, formed a partnership with Frontiers Health, a Switzerland-based firm focused on innovative healthcare solutions, particularly in digital health and telehealth integration. Through this collaboration, they aim to promote open innovation by tackling specific processes and therapeutic challenges. Their initiatives include organizing tailored events such as pitch competitions and hackathons, even adapting to virtual formats during the pandemic to sustain engagement and effectiveness.
Major companies in the catalepsy treatment market are directing their focus towards innovative products, such as baclofen oral granules, to drive revenue growth. Baclofen oral granules represent a specific form of baclofen medication formulated in granular or powder form for oral administration. For example, in June 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, introduced lyvispah to the market. Lyvispah is designed to work on spinal cord nerves, reducing the frequency and intensity of muscular spasms in individuals with specific spinal cord-related disorders. This innovative product is a strawberry-flavored, dissolvable granular formulation of baclofen, available in packets containing 5 mg, 10 mg, and 20 mg. It is accessible through specialist and retail channels, providing patients with a convenient and palatable treatment option.
In October 2022, Pfizer Inc., a pharmaceutical company based in the United States, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition is intended to bolster Pfizer's portfolio, while Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing shares to its shareholders. Biohaven Ltd. retains non-CGRP pipeline compounds and certain assets, with Pfizer owning about 3% of the new company's shares. Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology firm located in the US that focuses on developing therapeutic solutions, including treatments for catalepsy.
Major companies operating in the catalepsy treatment market include Upsher-Smith Laboratories LLC, Piramal Enterprises Ltd., Vintage Labs Private Limited, Hikma Pharmaceuticals plc, CASI Pharmaceuticals Inc., Covis Pharma GmbH, GSK plc, Bayer AG, Novartis AG, Aleva Neurotherapeutics SA, Sanofi S.A., Takeda Pharmaceutical Company Limited, Roche Holding AG, Abbott Laboratories, Pfizer Inc., Johnson & Johnson Services Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Eisai Co. Ltd., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Biogen Inc., Amgen Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Boehringer Ingelheim International GmbH.
North America was the largest region in the catalepsy treatment market in 2024. The regions covered in the catalepsy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catalepsy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Catalepsy treatment involves procedures aimed at alleviating symptoms such as loss of voluntary motion, fixed posture, and decreased pain sensitivity commonly associated with catalepsy. This treatment typically employs medications and muscle relaxants to reduce muscle rigidity.
The primary categories of catalepsy treatment include drugs, psychotherapy, and other therapeutic interventions. Drugs encompass various substances used to diagnose, treat, or alleviate symptoms of the condition. These medications are administered through oral, parenteral, and alternative routes, and are commonly utilized in hospitals, specialized clinics, and various other healthcare facilities catering to patients with catalepsy.
The catalepsy treatment market research report is one of a series of new reports that provides catalepsy treatment market statistics, including catalepsy treatment industry global market size, regional shares, competitors with a catalepsy treatment market share, detailed catalepsy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the catalepsy treatment industry. This catalepsy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The catalepsy treatment market consists of sales of benzodiazepines and zolpidem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The catalepsy treatment market size is expected to see strong growth in the next few years. It will grow to $123.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to investment and funding, global health trends, patient advocacy and awareness programs, healthcare policy changes, innovations in drug development. Major trends in the forecast period include collaborative research initiatives, neurostimulation therapies, regulatory landscape changes, patient advocacy and awareness, digital health integration.
The catalepsy treatment market is anticipated to experience growth due to the increasing prevalence of chronic diseases. Chronic conditions, characterized by lasting three months or longer and often progressing over time, impact a significant portion of the global population, particularly the elderly. Catalepsy, associated with toxic or infectious diseases linked to chronic illnesses, is on the rise, necessitating effective treatment. As of September 2022, the World Health Organization reported that approximately 41 million people, accounting for 74% of global deaths, succumb to chronic noncommunicable diseases (NCD) annually. Notably, 77% of NCD deaths occur in low- and middle-income countries. This escalation in chronic diseases is a driving force behind the growth of the catalepsy treatment market.
The increasing prevalence of neurological disorders is poised to contribute to the expansion of the catalepsy treatment market. Neurological disorders, encompassing various medical conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves, necessitate effective catalepsy treatment to manage symptoms, slow disease progression, enhance quality of life, and prevent or manage complications. According to The European Academy of Neurology, neurological disorders impact 1 in 3 individuals at some point in their lives, emphasizing the significant and widespread nature of these conditions. This growing prevalence of neurological disorders acts as a key driver for the catalepsy treatment market.
Product innovation is a significant trend gaining traction in the catalepsy treatment market. Leading companies in this field are concentrating on developing innovative solutions to enhance their market position. For example, in March 2024, Luigi Pavia, an Italy-based ecosystem engagement company, formed a partnership with Frontiers Health, a Switzerland-based firm focused on innovative healthcare solutions, particularly in digital health and telehealth integration. Through this collaboration, they aim to promote open innovation by tackling specific processes and therapeutic challenges. Their initiatives include organizing tailored events such as pitch competitions and hackathons, even adapting to virtual formats during the pandemic to sustain engagement and effectiveness.
Major companies in the catalepsy treatment market are directing their focus towards innovative products, such as baclofen oral granules, to drive revenue growth. Baclofen oral granules represent a specific form of baclofen medication formulated in granular or powder form for oral administration. For example, in June 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, introduced lyvispah to the market. Lyvispah is designed to work on spinal cord nerves, reducing the frequency and intensity of muscular spasms in individuals with specific spinal cord-related disorders. This innovative product is a strawberry-flavored, dissolvable granular formulation of baclofen, available in packets containing 5 mg, 10 mg, and 20 mg. It is accessible through specialist and retail channels, providing patients with a convenient and palatable treatment option.
In October 2022, Pfizer Inc., a pharmaceutical company based in the United States, acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition is intended to bolster Pfizer's portfolio, while Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing shares to its shareholders. Biohaven Ltd. retains non-CGRP pipeline compounds and certain assets, with Pfizer owning about 3% of the new company's shares. Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology firm located in the US that focuses on developing therapeutic solutions, including treatments for catalepsy.
Major companies operating in the catalepsy treatment market include Upsher-Smith Laboratories LLC, Piramal Enterprises Ltd., Vintage Labs Private Limited, Hikma Pharmaceuticals plc, CASI Pharmaceuticals Inc., Covis Pharma GmbH, GSK plc, Bayer AG, Novartis AG, Aleva Neurotherapeutics SA, Sanofi S.A., Takeda Pharmaceutical Company Limited, Roche Holding AG, Abbott Laboratories, Pfizer Inc., Johnson & Johnson Services Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Eisai Co. Ltd., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Biogen Inc., Amgen Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Boehringer Ingelheim International GmbH.
North America was the largest region in the catalepsy treatment market in 2024. The regions covered in the catalepsy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catalepsy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Catalepsy treatment involves procedures aimed at alleviating symptoms such as loss of voluntary motion, fixed posture, and decreased pain sensitivity commonly associated with catalepsy. This treatment typically employs medications and muscle relaxants to reduce muscle rigidity.
The primary categories of catalepsy treatment include drugs, psychotherapy, and other therapeutic interventions. Drugs encompass various substances used to diagnose, treat, or alleviate symptoms of the condition. These medications are administered through oral, parenteral, and alternative routes, and are commonly utilized in hospitals, specialized clinics, and various other healthcare facilities catering to patients with catalepsy.
The catalepsy treatment market research report is one of a series of new reports that provides catalepsy treatment market statistics, including catalepsy treatment industry global market size, regional shares, competitors with a catalepsy treatment market share, detailed catalepsy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the catalepsy treatment industry. This catalepsy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The catalepsy treatment market consists of sales of benzodiazepines and zolpidem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Catalepsy Treatment Market Characteristics3. Catalepsy Treatment Market Trends and Strategies4. Catalepsy Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Catalepsy Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Catalepsy Treatment Market34. Recent Developments in the Catalepsy Treatment Market
5. Global Catalepsy Treatment Growth Analysis and Strategic Analysis Framework
6. Catalepsy Treatment Market Segmentation
7. Catalepsy Treatment Market Regional and Country Analysis
8. Asia-Pacific Catalepsy Treatment Market
9. China Catalepsy Treatment Market
10. India Catalepsy Treatment Market
11. Japan Catalepsy Treatment Market
12. Australia Catalepsy Treatment Market
13. Indonesia Catalepsy Treatment Market
14. South Korea Catalepsy Treatment Market
15. Western Europe Catalepsy Treatment Market
16. UK Catalepsy Treatment Market
17. Germany Catalepsy Treatment Market
18. France Catalepsy Treatment Market
19. Italy Catalepsy Treatment Market
20. Spain Catalepsy Treatment Market
21. Eastern Europe Catalepsy Treatment Market
22. Russia Catalepsy Treatment Market
23. North America Catalepsy Treatment Market
24. USA Catalepsy Treatment Market
25. Canada Catalepsy Treatment Market
26. South America Catalepsy Treatment Market
27. Brazil Catalepsy Treatment Market
28. Middle East Catalepsy Treatment Market
29. Africa Catalepsy Treatment Market
30. Catalepsy Treatment Market Competitive Landscape and Company Profiles
31. Catalepsy Treatment Market Other Major and Innovative Companies
35. Catalepsy Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Catalepsy Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on catalepsy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for catalepsy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The catalepsy treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Drugs; Psychotherapy; Other Types2) by Route of Administration: Oral; Parenteral; Other Routes
3) by End User: Hospitals; Specialty Clinics; Other Users
Subsegments:
1) by Drugs: Antipsychotics; Antidepressants; Mood Stabilizers2) by Psychotherapy: Cognitive Behavioral Therapy (CBT); Supportive Therapy; Psychodynamic Therapy
3) by Other Types: Lifestyle Modifications; Alternative Therapies; Neuromodulation Techniques
Key Companies Mentioned: Upsher-Smith Laboratories LLC; Piramal Enterprises Ltd.; Vintage Labs Private Limited; Hikma Pharmaceuticals plc; CASI Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Catalepsy Treatment market report include:- Upsher-Smith Laboratories LLC
- Piramal Enterprises Ltd.
- Vintage Labs Private Limited
- Hikma Pharmaceuticals plc
- CASI Pharmaceuticals Inc.
- Covis Pharma GmbH
- GSK plc
- Bayer AG
- Novartis AG
- Aleva Neurotherapeutics SA
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Roche Holding AG
- Abbott Laboratories
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Dr. Reddy’s Laboratories Ltd.
- Mylan N.V.
- Eisai Co. Ltd.
- Glenmark Pharmaceuticals Limited
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Merck & Co. Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Biogen Inc.
- Amgen Inc.
- AstraZeneca plc
- GlaxoSmithKline plc
- Novo Nordisk A/S
- Boehringer Ingelheim International GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 92.7 Billion |
| Forecasted Market Value ( USD | $ 123.8 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 32 |
